Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sgs-742. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 known ✓ | O75899 | 3/20 | 1.00 |
| ▸ | GABBR1 known ✓ | Q9UBS5 | 3/20 | 1.00 |
| ▸ | GABRR1 | P24046 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sgs-742 SCHEMBL6024389 | 0.98 | GABBR2 (0.95) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL6351264 | 0.93 | GABBR2 (0.87) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL6356276 | 0.91 | GABBR2 (0.83) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL6354602 | 0.91 | GABBR2 (0.83) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL6358928 | 0.91 | GABBR2 (0.83) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL6360412 | 0.91 | GABBR2 (0.83) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL2353617 | 0.91 | GABBR2 (0.83) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL497185 | 0.87 | GABBR2 (0.76) | GABBR2GABBR1GABRR1 | |
| SCHEMBL673559 | 0.85 | GABBR2 (0.73) | GABBR2GABBR1GABRR1 | |
| SCHEMBL2701937 | 0.85 | GABBR2 (0.73) | GABBR2GABBR1GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2024191125-A1 | METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT | 연세대학교 산학협력단 | 2024-09-19 | — | — | WO | claimed |
| CN-117597628-A | Method for forming pattern | 三星SDI株式会社 | 2024-02-23 | — | — | CN | claimed |
| US-20240019784-A1 | METAL CONTAINING PHOTORESIST DEVELOPER COMPOSITION, AND METHOD OF FORMING PATTERNS INCLUDING STEP OF DEVELOPING USING THE COMPOSITION | SAMSUNG SDI CO., LTD. (KR) | 2024-01-18 | — | — | US | claimed |
| CN-117348341-A | Metal-containing photoresist developer composition and pattern forming method | 三星SDI株式会社 | 2024-01-05 | — | — | CN | claimed |
| WO-2009005519-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACCERA, INC. (US) | 2009-01-08 | — | — | WO | claimed |
| EP-1750724-A4 | METHOD FOR IMPROVING COGNITIVE FUNCTION BY CO-ADMINISTRATION OF A GABAB RECEPTOR ANTAGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR | UNIV JOHNS HOPKINS (US) | 2008-01-23 | — | — | EP | claimed |
| US-20080009467-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACCERA, INC. (US) | 2008-01-10 | — | — | US | claimed |
| EP-1750724-A1 | METHOD FOR IMPROVING COGNITIVE FUNCTION BY CO-ADMINISTRATION OF A GABAB RECEPTOR ANTAGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR | THE JOHNS-HOPKINS UNIVERSITY (US) | 2007-02-14 | — | — | EP | claimed |
| EP-1677758-A1 | COMPOSITIONS AND DOSAGE FORMS FOR ENHANCED ABSORPTION OF 3-AMINO-N-BUTYL-PHOSPHINIC ACID | ALZA Corporation (US) | 2006-07-12 | — | — | EP | claimed |
| EP-1372620-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | Saegis Pharmaceuticals (US) | 2004-01-02 | — | — | EP | claimed |
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | SAEGIS PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | claimed |
| WO-2002074293-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | SAEGIS PHARMACEUTICALS INC (US) | 2002-09-26 | — | — | WO | claimed |
| US-5545631-A | GAMMA-AMINOBUTYRIC ACID ANTAGONIST; TREATS PETIT-MAL TYPE EPILEPSIES | CIBA-GEIGY CORPORATION (US) | 1996-08-13 | — | — | US | claimed |
| EP-0463560-B1 | New antiepileptic agents | CIBA GEIGY AG (CH) | 1995-10-25 | — | — | EP | claimed |
| EP-0319482-B1 | Novel substituted propane phosphinic acid compounds | CIBA GEIGY AG (CH) | 1994-05-18 | — | — | EP | claimed |
| US-5300679-A | Antagonists to 4-aminobutyric acid | CIBA-GEIGY CORPORATION (US) | 1994-04-05 | — | — | US | claimed |
| EP-0463560-A1 | New antiepileptic agents | CIBA-GEIGY AG (CH) | 1992-01-02 | — | — | EP | claimed |
| EP-0319479-A2 | Substituted propane-phosphinic acid compounds | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | claimed |
| EP-0319482-A2 | Novel substituted propane phosphinic acid compounds | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | CRH, BDNF, CHAT | GABBR2 2093/4885GABBR1 1947/4885GABRR1 420/4885 |
| US-20080009467-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACHE, CHAT, BACE1 | GABBR2 3397/4885GABBR1 2987/4885GABRR1 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.